{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-24-000040","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.542555+00:00","generated_at":"2026-05-30T02:21:02.504041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alto Neuroscience Q3 net loss $16.8M; ALTO-100 fails Phase 2b MDD primary endpoint","bullets":["Net loss of $16.8M in Q3 2024 vs $9.1M a year ago; R&D expense $13.1M, G&A $5.8M.","Cash, cash equivalents & restricted cash ~$182M expected to fund operations into 2027.","ALTO-100 Phase 2b MDD missed primary endpoint; biomarker-positive mITT (n=196) not significant.","Adjunctive subgroup (n=61) showed clinically meaningful effect (Cohen's d=0.47, p=0.09); no MDD advancement planned.","Timelines: ALTO-300 & ALTO-203 topline 1H 2025; ALTO-101 topline 2H 2025; ALTO-100 bipolar depression topline 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-24-000040","json":"https://secwatch.observer/filing/0001999480-24-000040.json","markdown":"https://secwatch.observer/filing/0001999480-24-000040.md","text":"https://secwatch.observer/filing/0001999480-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/0001999480-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/alto-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:21:02.504041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}